Earlier this summer, the U.S. took a major step to confront Germany’s drug-pricing system, one that leaves American patients and companies carrying the costs of developing new, lifesaving medicines.
On June 18th, the U.S. Trade Representative launched a Section 301 investigation into whether Germany unfairly pushes down what it pays for innovative drugs in ways that harm U.S. commerce. The inquiry could lead to much-needed action if USTR finds Germany’s policies unreasonable or discriminatory.
While it’s a welcome first step, Germany is only one part of a much greater, international problem.
Many of the U.S.’s largest trading partners use government price controls to tamp down what they pay for new medicines. It’s called “foreign free-riding”: other large economies benefiting from pharmaceutical breakthroughs while the U.S. market supplies a disproportionate share of the R&D costs that support their development.
Japan, in particular, deserves special attention.
Japan is a major market for American medicines, but its pricing scheme sets artificially low drug prices and then repeatedly lowers them as sales increase. USTR’s 2026 Special 301 Report notes that Japan now effectively reviews drug prices every year. It can also impose additional cuts when a medicine sells better than expected, including reductions of up to 50% for some high-selling drugs.
Developing a new drug is expensive, uncertain work. It costs an average of $2.7 billion to bring a drug to market, and roughly 9 in 10 drugs that begin FDA clinical trials ultimately never reach patients.
Roughly two-thirds of new drugs brought to market over the last decade originated in the U.S. So when major economies systematically reduce the revenue that successful medicines can earn, they ultimately reduce the capital available for research, investment, job growth, and future drug development — most of which happens right here in the U.S.
Germany’s Section 301 investigation has put foreign drug pricing squarely on the U.S. trade agenda. While Germany is the first facing scrutiny, it should not be the last. If the U.S. is serious about protecting American innovation, investment, and jobs, it cannot confront foreign free-riding in one market while ignoring it in all others.